Skip to main content

Cabaletta Bio, Inc.

corporate_fare Company Profile

Cabaletta Bio, Inc.

CABA·NASDAQ·Life Sciences·CIK 0001759138

Cabaletta Bio, Inc. is a late clinical-stage biotechnology company that discovers and develops engineered T cell therapies for autoimmune diseases. The company's proprietary CABA®, or Cabaletta Approach to B cell Ablation platform, utilizes the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach to potentially reset the immune system. This platform aims to enable complete and durable responses for a broad range of autoimmune diseases and has potential applicability across dozens of identified, evaluated, and prioritized autoimmune diseases. The company's lead product candidate within the CARTA strategy is Resecabtagene autoleucel, or rese-cel (formerly CABA-201). Rese-cel is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat a broad range of autoimmune diseases. It is engineered to achieve transient and deep depletion of all B cells following a single, weight-based infusion of T cells. This process allows for the deep elimination of all disease-contributing B cells, followed by repopulation with healthy transitional, naïve B cells, potentially resetting the immune system and leading to clinical responses without chronic therapy. The efficacy and safety of rese-cel were reviewed in a February 2026 Nature Biotechnology publication. In December 2025, the company initiated a registrational trial for rese-cel in patients with dermatomyositis or anti-synthetase syndrome.

Cabaletta Bio, Inc. (NASDAQ:CABA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for CABA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Cabaletta Bio Reports Substantial Doubt About Going Concern, Increased Losses, and Details of Recent Capital Raises Amidst Clinical Progress
  • Cabaletta Bio Reports Q4/FY2025 Results, Secures $30M, Advances Lead CAR T Program Towards 2027 BLA
  • Cabaletta Bio Targets 2027 Myositis BLA, Details Key Clinical Milestones & 1H26 Data
  • Cabaletta Bio Initiates Pivotal Myositis Trial, Secures FDA Alignment for Lupus, and Advances Automated Manufacturing for rese-cel

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$167.86M
Diluted EPS
-$2.10
Op. Cash Flow
-$131.08M
Free Cash Flow
-$132.31M
Operating Income
-$172.24M
Cash & Equivalents
$82.98M
Debt / Equity
0.00×
Shares Outstanding
100.48M sh
Source: 10-K · filed 2026-03-23 · accession 0001759138-26-000011
$0.9699 +3.61% today
52-week range · as of 2026-11-05 $0.9699 – $4.23
Market cap
$201.94M
Volume
3.7M (0.8× avg)
3-mo avg 4.8M
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CABA - Filings & News (Page 2)

CABA
Mar 23, 2026, 7:36 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $0.9699 info
Change: -$2.02 (-68%) info
Market Cap: $201.936M info
CABA
Mar 23, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $0.9699 info
Change: -$2.02 (-68%) info
Market Cap: $201.936M info
CABA
Mar 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $0.9699 info
Change: -$2.02 (-68%) info
Market Cap: $201.936M info
CABA
Jan 12, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.10
Real-time Price: $0.9699 info
Change: -$1.13 (-54%) info
Market Cap: $201.936M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets